Alzheimer's disease (AD) is hypothesized to be caused by an overproduction or reduced clearance of amyloid-b (Ab) peptide. Autosomal dominant AD (ADAD) caused by mutations in the presenilin (PSEN) gene have been postulated to result from increased production of Ab42 compared to Ab40 in the central nervous system (CNS). This has been demonstrated in rodent models of ADAD but not in human mutation carriers. We used compartmental modeling of stable isotope labeling kinetic (SILK) studies in human carriers of PSEN mutations and related noncarriers to evaluate the pathophysiological effects of PSEN1 and PSEN2 mutations on the production and turnover of Ab isoforms. We compared these findings by mutation status and amount of fibrillar amyloid deposition as measured by positron emission tomography (PET) using the amyloid tracer Pittsburgh compound B (PIB). CNS Ab42 to Ab40 production rates were 24% higher in mutation carriers compared to noncarriers, and this was independent of fibrillar amyloid deposits quantified by PET PIB imaging. The fractional turnover rate of soluble Ab42 relative to Ab40 was 65% faster in mutation carriers and correlated with amyloid deposition, consistent with increased deposition of Ab42 into plaques, leading to reduced recovery of Ab42 in cerebrospinal fluid (CSF). Reversible exchange of Ab42 peptides with preexisting unlabeled peptide was observed in the presence of plaques. These findings support the hypothesis that Ab42 is overproduced in the CNS of humans with PSEN mutations that cause AD, and demonstrate that soluble Ab42 turnover and exchange processes are altered in the presence of amyloid plaques, causing a reduction in Ab42 concentrations in the CSF.
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INTRODUCTION
The pathogenic causes of Alzheimer's disease (AD) are not fully understood, partly due to the difficulty in demonstrating the steps that lead to dementia in humans. However, rare autosomal dominant AD (ADAD) can be predicted with nearly 100% certainty in individuals with specific mutations in the genes encoding presenilin 1 (PSEN1), presenilin 2 (PSEN2), or the amyloid precursor protein (APP) (1) . Recent findings suggest that a series of pathophysiological changes occur in the brains of ADAD mutation carriers decades before clinical dementia manifests (2) . The amyloid hypothesis (3) predicts that AD is caused by increased production or decreased clearance of amyloid-b (Ab) in the brain, resulting in amyloidosis and a pathological hallmark of AD, amyloid plaques. Ab is produced from the C-terminal fragment of APP by cleavage of APP by b-secretase to form C99, followed by cleavage of C99 by PSEN1 or PSEN2, the enzymatic components of g-secretase (4). The principal peptide produced by g-secretase is a 40-amino acid peptide (Ab40), but this enzymatic cleavage lacks specificity and peptides ranging in length from 38 to 43 amino acids are produced (5) . Ab42 has attracted considerable attention because it has greater amyloidogenic properties and is the principal component of amyloid plaques (6) . In support of the amyloid hypothesis, an APP mutation that reduces Ab production is associated with a strong protective effect against AD (7), whereas duplication of APP or mutations that are thought to increase total Ab species or Ab42 relative to Ab40 cause dominantly inherited AD (8) (9) (10) . In cell culture and in plasma from human ADAD participants, PSEN mutations have been reported to increase the Ab42/Ab40 ratio (11) (12) (13) (14) , which is hypothesized to increase the risk of amyloidosis (15) . However, others have found that neither the Ab42/Ab40 ratio nor Ab42 concentrations are increased in vitro (16) . Furthermore, findings of reduced Ab42 concentrations in the cerebrospinal fluid (CSF) of ADAD participants (13, 17) do not directly support the hypothesis that increased Ab42 production is an etiological mechanism in dominantly inherited AD.
We previously used stable isotope labeling kinetics (SILK) to examine the turnover kinetics of Ab in sporadic late-onset AD (18) . Both sporadic AD and ADAD are associated with lower CSF Ab42 concentrations and Ab42/Ab40 ratios (13, 17, (19) (20) (21) . However, PSEN mutations in ADAD are hypothesized to cause increased Ab42 production (4, 12, 22) , although direct evidence for increased in vivo production of Ab42 in humans has not been reported.
We hypothesized that the central nervous system (CNS) Ab42/Ab40 production rate ratio is increased in PSEN1 and PSEN2 mutation carriers compared to noncarriers. To address this hypothesis, we performed in vivo SILK studies in participants with ADAD mutations and sibling noncarrier controls. A comprehensive compartmental model was developed to determine steady-state metabolic kinetic parameters including fractional turnover rates (FTRs) and production rates of Ab38, Ab40, and Ab42 for each participant. The Ab kinetic parameters were compared to the presence of a PSEN mutation and insoluble amyloid deposition, which was measured by positron emission tomography (PET) imaging of Pittsburgh compound B (PIB).
RESULTS
SILK was performed in 11 individuals who carry mutations in PSEN associated with ADAD and in 12 sibling control persons who do not carry PSEN mutations. PIB-PET imaging (23) showed virtually no detectable amyloidosis in all noncarriers and in four of the mutation Ab42/Ab40 (red triangles)] and as enrichment ratios normalized to plasma leucine plateau enrichments [C, lower panel: Ab38 (blue circles), Ab40 (green squares), and Ab42 (red triangles)]. Ab38 and Ab40 present similar labeling profiles in all subject groups, whereas Ab42 kinetics deviate from Ab38 and Ab40 only in mutation carriers, as evident in the Ab42/Ab40 and Ab42/Ab38 ratio profiles. Data points represent the means ± SD for group-averaged values, and the solid lines represent the model fits to the data using the model in Fig. 2 .
carriers (denoted PIB
− ), and considerable amyloidosis in seven mutation carriers (denoted PIB + ) (Fig. 1A) . A mean cortical binding potential (MCBP) score was calculated from the PET images to obtain a continuous quantitative covariate for statistical analyses.
Differential Ab isoform kinetics by mutation and amyloid deposition Plasma leucine enrichment approximated a constant plateau during the 9-hour intravenous 13 C 6 -leucine infusion, and then rapidly decreased after the infusion was stopped (fig. S1 ). The 13 C 6 -leucine isotopic enrichments of Ab38, Ab40, and Ab42 recovered from CSF were compared between mutation carriers, with or without amyloidosis, and nonmutation carriers to address the relationship between Ab isoform metabolic kinetics, mutation status, and amyloid deposition.
To compare Ab isoform kinetics, we plotted ratios of labeled Ab isoform enrichments in the CSF so that a ratio of 1 indicates the same isotopic enrichment and kinetics between Ab isoforms. The Ab38/Ab40 labeling ratio was about 1 from 5 to 36 hours in all participant groups (Fig. 1B , no significant group by time interaction), indicating similar kinetics between Ab38 and Ab40. Similarly, the Ab42/Ab40 and Ab42/Ab38 labeling ratios were nearly constant at 1 over time in noncarriers. However, in mutation carriers, the Ab42/Ab40 and Ab42/Ab38 labeling ratios were elevated during early time points and decreased at later time points (Fig. 1B ) in relation to plaque status. Repeatedmeasures analysis of variance (ANOVA) revealed a significant group by time interaction for both the Ab42/Ab40 and Ab42/Ab38 labeling ratios (P < 0.0001), with a significant linear contrast (P < 0.01) between groups at ≤9 hours and at ≥18 hours, showing an increasing magnitude of effect (noncarrier < mutation carrier PIB − < mutation carrier PIB + ). The Ab isoform enrichment mismatch was more pronounced in participants with amyloid deposition (PIB + ), caused by an earlier and lower Ab42 peak with a flatter terminal tail compared to Ab38 and Ab40 (Fig. 1C) . The time to reach peak 13 C labeling in each Ab isoform was measured for each participant. The Ab38/Ab40 peak time ratio was not different between mutation carrier and noncarrier groups (1.01 ± 0.01 versus 1.00 ± 0.01, respectively). In contrast, Ab42 peaked at the same time as did Ab40 in the noncarrier group (Ab42/Ab40 peak time ratio = 1.01 ± 0.03), whereas Ab42 peaked significantly earlier than did Ab40 in the mutation group (peak time ratio = 0.93 ± 0.05; P = 0.015, for mutation effect; P < 0.001, for PIB MCBP score).
A multicompartment model to describe Ab isoform kinetics A comprehensive compartmental model was developed to quantify steady-state Ab isoform kinetic parameters for each participant data set. The model incorporated the plasma leucine, Ab enrichment time course profiles, and the CSF Ab isoform concentrations for each subject (schematically depicted in Fig. 2 13 C 6 -leucine, APP production and processing to C99 peptide, and Ab38, Ab40, or Ab42 production from C99. The labeled Ab38, Ab40, and Ab42 that are sampled in CSF are presumed to be soluble within the "brain" compartment. The soluble Ab peptides may exchange with other unlabeled Ab structures, may be transported to CSF, or may be lost because of other processes (for example, transport to blood, plaque deposition, or cellular degradation). Transport through CSF is modeled as a three-compartment time delay.
irreversible loss of each soluble Ab isoform that was not recovered in CSF. The rate constants for transfer between compartments in the model were optimized for each participant, and mean values for each parameter are summarized in Table 1 . The model describes three fundamental processes that affect Ab kinetics-production, reversible exchange, and irreversible loss-and accounts for the effect of these processes on CSF Ab concentrations.
Increased Ab42 and Ab42/Ab40 production with PSEN mutations regardless of amyloid deposition The mutation carriers had an 18% higher absolute Ab42 production rate (P < 0.05, for mutation effect) and a 24% higher Ab42/Ab40 production rate ratio (P < 0.0001, for mutation effect) than the nonmutation carriers, whereas amyloid load as measured by PIB-PET did not have a significant effect on Ab42 production rate ( Table 2 , Fig. 3A, and fig. S5 ). There were no differences in Ab38 or Ab40 absolute production rates or the Ab38/Ab40 production rate ratio between carrier and noncarrier groups ( Table 2) .
Exchange process required to fit Ab kinetic curves To optimally fit the shape and peak magnitude of Ab isoform enrichment time courses, a compartment was required to model reversible exchange of newly synthesized labeled Ab peptides with a preexisting pool of unlabeled Ab (Fig. 2) . The exchange process was of minimal magnitude in nonmutation carriers, in which only~10% of the flux of newly synthesized Ab38, Ab40, or Ab42 underwent exchange ( Table 2 ).
The percent of Ab38 and Ab40 that underwent exchange was not significantly different between mutation carriers and noncarriers. However, the exchange for Ab42 was significantly greater in carriers compared to the noncarriers (51 ± 58% versus 6 ± 12% of flux, respectively; P = 0.004, for mutation effect; P = 0.001, for PIB status) ( Table 2 ). The exchange process for Ab42, combined with a faster turnover rate of Ab42 (see below), provided an excellent fit to the entire shape of the Ab42 enrichment time course in all groups including mutation carriers with amyloid deposition (mean R 2 for all participants of 0.994, 0.995, and 0.987 for Ab38, Ab40, and Ab42, respectively).
Higher irreversible loss of Ab42 in amyloid deposition
The FTR (pools per hour) of soluble Ab is the rate constant for irreversible loss of soluble Ab to all metabolic fates; this process is kinetically distinct from reversible exchange. The physiology of the system suggests that the FTR includes irreversible losses to the CSF or bloodstream, degradation, and deposition into amyloid plaques. The Ab40 FTR was significantly slower in PIB + compared to PIB − participants (P = 0.024, for PIB MCBP score) and trended toward significance for Ab38 (P = 0.054, for PIB MCBP score), but neither was affected by mutation status (Table 2 and Fig. 3B ). This decreased turnover rate correlated with the extent of amyloidosis measured by PET PIB. In contrast, Ab42 FTR trended toward an increase in mutation carriers (P = 0.065, for mutation effect) independent of amyloid load (Table 2 and Fig. 3B ). The Ab38/Ab40 FTR ratio was not significantly different between noncarrier and mutation carrier groups, but the Ab42/Ab40 FTR ratio was 65% higher in mutation carriers (P < 0.002, for both mutation status and PIB MCBP score) ( Table 2 and Fig. 3B ).
Decreased CSF Ab42 concentrations only during amyloid deposition
The measured basal concentrations of CSF Ab isoforms were compared by mutation status and PIB MCBP score (Table 2 and Fig. 3C ). The Ab42 CSF concentration and the Ab42/Ab40 CSF concentration ratio were significantly reduced in association with amyloid deposition (P = 0.003, for PIB MCBP score; not significant by mutation status), whereas there were no differences between groups for the CSF Ab38, Ab40, or Ab38/Ab40 concentration ratio (Table 2) .
DISCUSSION
Our study of in vivo CNS Ab isoform kinetics in participants with PSEN mutations confirms the hypothesis that the production rate of Ab42 is increased relative to Ab40 in humans with PSEN mutations associated with ADAD, and also revealed increased exchange of soluble Ab42 and increased irreversible loss of soluble Ab42 associated with the presence of fibrillar amyloid plaques. The finding of increased Ab42 production was predicted by some in vitro studies (11, 12) and evidence of altered g-secretase function in carriers of PSEN1 or PSEN2 ADAD mutations (24) . Here, we directly quantify increased Ab42 production in vivo in humans because of mutations that cause ADAD, and confirm that such mutations increase CNS Ab42 production rates in vivo. The ratio of Ab42 to Ab40 production rates was greater than 15% for almost all mutation carriers (average, 17.4%), whereas noncarriers were less than 15% (average, 14%), suggesting tight physiological control that is disrupted in the presence of a mutation. There was a~25% relative increase in Ab42 to Ab40 production rate in mutation carriers, which correlates 
0.020 ± 0.038 0.000 ± 0.000 0.000 ± 0.000 with the 40% decrease in Ab production because of a mutation that is protective for the development of AD (7). Changes in the Ab42 to Ab40 production rate ratio are likely to have a large impact on the rate of Ab42 deposition into plaques because in vitro studies have demonstrated that even relatively small changes in the Ab42/Ab40 ratio significantly affect aggregation kinetics and morphology (15) that could promote plaque formation. The Ab42/Ab40 ratio and the total amount of Ab42 have been hypothesized to affect the age of onset of ADAD (25) . Some PSEN mutations in cultured cells in vitro have been reported to decrease Ab40 production or loss of overall Ab production (16); however, our in vivo SILK studies did not confirm decreased Ab40 or total Ab production. Our finding of a faster irreversible FTR of soluble Ab42 relative to Ab38 or Ab40 in the presence of PSEN mutations or plaques was not anticipated. This faster relative FTR was a primary factor causing the Ab42 isotopic enrichment curve to peak earlier than Ab38 or Ab40 in the presence of amyloidosis (Fig. 1) . We cannot determine the physiological mechanisms that underlie this irreversible FTR, but it includes all losses of soluble Ab peptides including transport into CSF or plasma, proteolytic degradation, and deposition into amyloid plaques. The rate constant for transport to CSF is likely to be similar for all Ab isoforms because the transport of soluble Ab isoforms to CSF is driven by fluid flow (26) . Therefore, the faster relative FTR of Ab42 in the presence of plaques implies a greater loss of Ab42 from the system to fates other than CSF. Although we cannot identify the specific fates of peptides permanently lost from the system, our observations are consistent with increased deposition of Ab42 into amyloid plaques (27, 28) relative to Ab38 and Ab40, which subsequently causes increased Ab42 in brain plaques (29) , as shown in video S1, and a reduction in the amount of Ab42 recovered in CSF (30) . Our finding of increased irreversible FTR of Ab42 in subjects with PSEN mutations but no amyloid load suggests that increased Ab42 deposition may be occurring in these subjects, and SILK studies of Ab42 turnover kinetics may provide a sensitive window into altered processes before amyloidosis is detectable by PET PIB.
Another unanticipated finding was a reversible exchange process whereby a portion of newly synthesized (that is, isotopically labeled) peptides exchange with preexisting unlabeled Ab. The structures of the preexisting unlabeled Ab cannot be determined from this tracer study, but they could potentially consist of oligomers or aggregates (31, 32) or may reflect reversible binding of Ab42 to the surface of Table 2 . CSF Ab isoform concentrations and selected model kinetic parameters. Parameters were determined on the basis of the best fit to a compartmental model of Ab turnover and production. Outcomes were compared by mutation status using ANOVA after adjusting for fibrillar amyloid deposition by treating PIB MCBP score as a covariate. Kinetic parameters are identified with terminology (Fig. 2) . P < 0.05, in bold. IP, immunoprecipitation.
Noncarriers (n = 12)
Mutation carriers (n = 11) P* †Analyzed by nonparametric Mann-Whitney U test because of nonnormal distribution, based on mutation status and PIB status (rather than PIB MCBP score).
‡No exchange observed in any subject.
amyloid plaques before structural alterations cause permanent assimilation into plaques (33, 34) . We previously reported that late-onset AD was associated with a slower clearance rate for Ab40 and Ab42 based on a monoexponential slope applied to the terminal phase (24 to 36 hours) of the SILK enrichment time course (18) . The present study used a compartmental model to fit the SILK enrichment time courses over the full experimental period (0 to 36 hours) in a manner consistent with known physiological processes (35) . This compartmental model confirms the previous report that the FTR is slower for Ab40 with increased insoluble amyloid plaque deposition ( Table 2 ). The exchange process described by our compartmental model was minimal for Ab38 and Ab40 in the presence ) evidence of amyloid deposition. Each parameter was measured for Ab38 (first column), Ab40 (second column), Ab42 (third column), and the Ab42/Ab40 ratio (fourth column), and compared by mutation status and amyloid deposition. Error bars indicate 95% confidence intervals. Mutation status compared when amyloid deposition did not affect magnitude or significance. *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA based on mutation status with PIB MCBP score as a covariate. Blue circles, noncarriers; green squares, mutation carrier PIB (Table 2) , and thus, the terminal tail approximates a monoexponential shape for these isoforms. The observation that the irreversible FTRs of Ab38 and Ab40 are negatively correlated with PIB MCBP score (Table 2) suggests that the presence of plaques substantially alters physiological processes (for example, fluid flow perfusion through brain tissue) and thus retards the transfer of soluble Ab peptide from the brain to CSF. An outcome of this decreased transport to the CSF may be loss of the normal physiological diurnal pattern of CSF Ab concentrations (36, 37) . Several caveats about the compartmental model limit the ability to completely resolve the system. Flow processes likely dictate the rate at which Ab peptides transit from brain to the lumbar space. These processes are approximated here as a sequential series of compartments. More elaborate models that account for brain and subarachnoid space anatomy and flow may allow more accurate determination of the rates of Ab peptide irreversible loss and production. The current data set is also not rich enough to identify the rates of production and irreversible loss of APP and C99. Additional kinetic data relevant to the production and irreversible loss of APP and C99 would improve the estimation of Ab production and irreversible loss rate constants. Also, measurement of concentrations of various Ab peptides has a large impact on the estimates of the production rate constants for the Ab peptides.
The present study also confirms that the terminal slope of the Ab42 enrichment curve is slower in the presence of plaques. We observed that Ab42 irreversible FTR was increased in the presence of PSEN mutations independent of plaque load. The SILK tracer technique thus reveals abnormalities in Ab42 before plaques are detectable by PET PIB. Indeed, three of the four mutation carriers who did not have detectable amyloid plaques by PET PIB had features of Ab42 kinetics that were more similar to mutation carriers with amyloid plaques than to noncarriers, including Ab42/Ab40 FTR ratio >1.1, and evidence of Ab42 exchange ( fig. S2 ). These features strongly suggest that plaque development or some form of Ab aggregation has been initiated in these individuals, but fibrillar plaque load has not reached the threshold of PET PIB detection. In contrast, only one mutation carrier who was PET PIB-negative had no evidence of Ab42 exchange. This participant also had the highest Ab42/Ab40 CSF concentration ratio (0.215; fig. S4 ) of all participants in our study (compare to figs. S2 and S3; this ratio was 27% higher than the next highest concentration ratio observed in individual participants, 0.169), demonstrating that elevated Ab42/Ab40 CSF concentration ratios are only observed in ADAD persons in the absence of amyloid plaques. Because amyloid deposition in the caudate may be one of the earliest deposition events, we evaluated caudate PIB as a sensitive measure of amyloid deposition. The caudate PIB and MCBP PIB were highly correlated with each other with a Pearson correlation coefficient of 0.94 (P = 5 × 10 ); no kinetic parameters changed significance with amyloidosis as measured by caudate PIB.
Our findings offer a context for the recent report that CSF Ab42 concentration is elevated in ADAD individuals decades before predicted age for onset of clinical symptoms of dementia, and then drops below normal as plaques develop (2, 38) (see Fig. 4 for schematic of proposed process). Our finding of increased Ab42 production in mutation carriers regardless of the amount of amyloid deposition indicates that increased Ab42 production precedes amyloid deposition, and likely occurs decades before the onset of dementia and is possibly present throughout life. The long delay in the emergence of plaque deposits of Ab42 even in the presence of overproduction of Ab42 suggests the presence of an initial slow process (for example, initial Ab nucleation event in which monomeric Ab forms small aggregates) followed by a growth phase of Ab polymerization (39) . We therefore hypothesize that Ab42 production rate (solid gold line, Fig. 4 ) remains above "normal" (solid black line) throughout life because of their PSEN genotype. ADAD individuals have an increased irreversible loss of soluble Ab42 (FTR solid red line, Fig. 4 ) that tracks or precedes PET-detectable amyloid deposition, consistent with a faster removal of soluble Ab42 as it is deposited into plaques. This results in a decreased recovery of Ab42 in the CSF, accounting for the decrease in CSF Ab42 concentration (solid blue line, Fig. 4 ) as plaque development proceeds (solid green line, Fig. 4) . The physiological identity of the pool(s) in exchange with newly labeled soluble Ab42 identified by SILK (dotted black lines, Fig. 4 ) cannot be determined in this study. If exchange occurs with micelles or oligomers, exchange may precede PET-detectable amyloid deposition (dotted line 1, Fig. 4 ). If exchange is with plaque surfaces, it may track or even lag behind amyloid deposition (dotted lines 2 and 3, Fig. 4 ). Future studies with greater numbers of participants or longitudinal designs will be required to resolve this question.
Although ADAD represents less than 1% of all AD cases, it has been informative for elucidating the pathophysiology of AD and can manifest as late-onset AD indistinguishable from the more idiopathic forms (40) . The findings of this study further support the amyloid hypothesis and provide quantitative estimates of lifelong increases in Ab42 production that may cause AD in humans. Further, these results indicate profound changes in Ab kinetics in the presence of amyloid plaques. With increased understanding of the pathogenic causes of AD and the quantitative changes associated with AD pathology, it is hoped that better tests and directed therapeutics can be developed in the future.
MATERIALS AND METHODS

Study design
This study took place at the Washington University School of Medicine in St. Louis and was approved by the Human Research Protection Office. Fig. 4 . Potential scheme for the time course of plaque deposition in ADAD. The solid black line signifies normal for each measure. The production rate of Ab42 relative to Ab40 (gold) remains constant throughout life before and during plaque deposition (production rate was different by mutation status but not by amyloid deposition). CSF concentration of Ab42 (blue) starts elevated above normal because of overproduction and then decreases to below normal because of an increase in the FTR (red) of Ab42 relative to Ab40. As the amount of amyloid plaques increases over time (green), the extent of Ab42 exchange (dotted) may precede (for example, if due to oligomer formation), follow closely, or lag behind amyloid deposition (for example, if due to reversible interaction with amyloid plaques).
All participants completed informed written consent. Two groups of volunteers were enrolled in the study: (i) ADAD mutation carriers either with (n = 7) or without (n = 4) amyloid deposition and (ii) related family members at risk for carrying a mutation but who do not carry ADAD mutations (n = 12).
Binding of [ 11 C]PIB-PET was used to test for deposition of amyloid plaques in the brain (23) . Binding potentials using the cerebellum as a reference region were determined for the prefrontal cortex, precuneus, lateral temporal cortex, and gyrus rectus. The PIB MCBP score was determined by averaging these binding potentials together. A PIB MCBP score of 0.18 was considered evidence of amyloid deposition (PIB + ), and a PIB MCBP score of less than 0.18 was considered to be amyloid deposition-negative (PIB − ). The highest PIB MCBP score in noncarriers was 0.12.
Participant demographics
Twenty-three participants from nine pedigrees (PSEN1 Ala79Val, Leu226Arg, His163Arg, Met146Leu, Met139Ile, Gly217Arg, Ala246Glu, and PSEN2 Asn141Ile) completed Ab SILK studies. Twelve (52%) of the participants were male. The average age of mutation carriers was 43.2 ± 12.7, and that of noncarriers was 47.7 ± 14.8 (P > 0.05). Eight PSEN1 mutation carriers and three PSEN2 mutation carriers were included in the analysis with sibling controls. Two mutation carriers were rated as having prodromal dementia and one with mild dementia. Eight mutation carriers were cognitively asymptomatic, as were all noncarriers. Seven mutation carriers were PIB + , and four of the mutation carriers and all noncarriers were PIB − ; the average PIB MCBP score was significantly different between groups, 0.03 ± 0.04 versus 0.43 ± 0.45 for noncarriers and mutation carriers, respectively (P = 0.005). At least one APOE e4 allele was present in 33% (n = 4) of the noncarrier group, 25% of the mutation carrier PIB − group, and 28% of the mutation carrier PIB + group (P > 0.05).
Sample collection
The SILK clinical study followed the procedure previously described (41) . Briefly, intravenous and intrathecal lumbar catheters were placed between 7:30 and 9:00 a.m., and the collection of samples was started between 8:00 and 9:30 a.m. After initial CSF and plasma baseline samples were collected, participants were infused with a bolus of L-[U-
13
C 6 ]leucine (3 mg/kg) for 10 min, followed by 2 mg/kg per hour for the remainder of the first 9 hours. For the 36 hours of the study, 6 ml of CSF was obtained every hour; afterward, the catheters were removed, and participants remained on bed rest for 12 hours. Aliquots of CSF were frozen at −80°C immediately in 1-ml polypropylene tubes after being collected. Venous blood samples (12 ml) were obtained at hourly intervals from 1 to 13 hours and then at 17 and 36 hours, and plasma was stored at −80°C for the determination of plasma leucine enrichment.
Analysis of CSF samples
All procedures relating to clinical studies, sample processing, and sample analysis were performed blinded to mutation, clinical, and amyloid status. At each hour of collection, 1 ml of CSF was thawed, and Ab was immunopurified and isotopic enrichment of Ab isoforms was measured with liquid chromatography-mass spectrometry (MS) similar to previous studies (18) , except for dedicated measurement of Ab38, Ab40, and Ab42 C-terminal peptides.
Measurements of Ab38, Ab40, and Ab42 C-terminal peptides A mid-domain antibody (HJ5.1, anti-Ab [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] ) was covalently bound to CNBr Sepharose beads and stored in a 50% slurry of 0.02% phosphatebuffered saline/azide at 4°C. The immunopurification mixture was composed of 800 ml of CSF; 20 ml of a solution containing 12 
C
15 N Ab40, Ab42, and Ab38 for quantification by internal standard; and 12.5 ml of 100× protease inhibitor, 110 ml of 5 M guanidine, and 30 ml of antibody-bead slurry. Beads were rotated in an Eppendorf Axygen tube for 2 hours at room temperature and rinsed with 0.5 M guanidine followed by two rinses of 25 mM ammonium bicarbonate. All liquid was removed by aspiration, and then neat formic acid was added to elute Ab from the antibody-bead complex. The formic acid supernatant was transferred to a new polypropylene tube and dried in a vacuum dryer (Labconco CentriVap). The sample was reconstituted with 25 ml of 25 mM ammonium bicarbonate and digested with 2.5 ng of Lys-N overnight at 37°C. This solution was dried in the speed vacuum and resuspended in 10% formic acid and 20% dimethyl sulfoxide. Three microliters of this sample was injected into a nanoACQUITY Ultra Performance Liquid Chromatography system and then analyzed by a XEVO TQ-S mass spectrometer (Waters). MassLynx V4.1 was used to quantify the MS data. For determination of plasma 13 C 6 -leucine enrichment, amino acids were recovered from plasma with cation exchange chromatography and converted to N-heptafluorobutyryl n-propyl ester derivatives, and isotopic enrichment [mass/charge ratio (m/z) 349 and 355] was measured with gas chromatography (GC)-negative chemical ionization-MS (Agilent 6890N Gas Chromatograph and Agilent 5973N Mass Selective Detector) as described (42) . The GC-MS instrument response was calibrated with gravimetric standards of known isotope enrichment.
Compartmental model for Ab38, Ab40, and Ab42 kinetics A comprehensive steady-state compartmental model that accounts for the full time course of Ab38, Ab40, and Ab42 enrichments and CSF concentrations was developed; a diagram of the model is shown in Fig. 2 . The model consists of a series of interconnected compartments with first-order rate constants that describe the transfer of labeled species between compartments. Modeling was performed with SAAM II (Resource for Kinetic Analysis, University of Washington, Seattle, WA). The model consists of three parallel arms, one for each Ab isoform. The enrichments of plasma leucine and CSF Ab peptides were measured at frequent time intervals (indicated by solid triangles). Plasma leucine is used as the tracer precursor for CSF Ab peptides because we have shown that, given a sufficiently long infusion, CSF Ab enrichments essentially match that of plasma leucine in monkeys (43) . A "forcing function" was used to describe the time course of plasma 13 C 6 -leucine enrichment with a linear interpolation between measured samples.
Preliminary modeling revealed that the isotopic enrichment time course for each Ab isoform could be optimally described by a single compartment coupled with a long time delay that consisted of five subcompartments. On the basis of known physiology, two of these delay compartments (representing APP and C99 peptides) were placed in front of the compartments that represent the brain "soluble" Ab peptides because in vivo tracer studies in mice show that APP and C99 have relatively long half-lives (~3 hours) (44) that should contribute to the overall time delay before labeled Ab is detected at the lumbar sampling site. The remaining three delay compartments were placed after the soluble Ab compartments to represent perfusion of labeled peptides through brain tissue and heterogeneous CSF fluid transport processes.
Given that preliminary modeling indicated that a single time delay process could be identified within the data, the turnover rates for APP, C99, and each of the three CSF delay compartments were set to a single adjustable parameter that affects the overall time delay.
The model takes into consideration that some of the C99 and soluble Ab peptides are metabolized to fates other than Ab peptides that appear at the CSF sampling site. The physiological nature of these other losses for soluble Ab peptides is unknown but includes all processes that remove soluble peptides irreversibly, for example, deposition into plaques, cellular uptake, and proteolytic degradation. A compartment in exchange with the soluble Ab peptide was necessary to optimally fit the sigmoid shape of the CSF Ab enrichment time courses after the peak enrichment, particularly for Ab42 in the mutation carrier PIB + group; this exchange process was added for an isoform only if it improved the Akaike information criteria (AIC) of the fit as provided by SAAM II. A scaling factor was applied to each of the Ab isoform enrichments if it improved the AIC to account for small amounts of isotopic dilution between plasma leucine and the biosynthetic precursor pool (generally <5%) or to correct for minor calibration errors (generally <10%) in the measurement of isotope enrichments of plasma leucine or Ab peptides.
On the basis of the optimized kinetic parameters that describe the shape and magnitude of the CSF Ab enrichment time course, the model determines the rate constant (pools per hour) for production of each Ab peptide from their common C99 precursor to accurately project the measured baseline CSF Ab peptide concentrations. The model projects the steady-state masses (ng) within and the flux rates (ng/hour) between all compartments for each Ab isoform.
Statistical analyses
Ratios of isotopic enrichments between peptides at all time points were analyzed by repeated-measures ANOVA. When the time by group interaction was significant, enrichment ratios at individual time points were analyzed by ANOVA with a linear contrast to test for significant group effects. ANOVA was performed with a mutation status main affect, adjusting for PIB MCBP score as a covariate. Variables were tested for normal distribution by Shapiro-Wilk criterion; variables that were not normally distributed were log-transformed before performing ANOVA. The distribution of rate constants describing the exchange process revealed by the model was analyzed by Mann-Whitney U test because log transformation did not normalize the distribution. Statistics were performed with IBM SPSS version 20. A P value of <0.05 was considered to be statistically significant. Unless otherwise noted, results shown are mean ± SD for normally distributed variables or as median with interquartile range for nonnormally distributed variables. Graph generations were performed in GraphPad Prism version 5.01 for Windows (GraphPad Software).
Movie methods
A video illustrating the isotope labeling model for soluble Ab42 and Ab40 was created with Matplotlib (41) . Compartments for soluble, exchange, and irreversible loss (plaque) are shown over the MNI152 template image included as part of the FMRIB Software Library (42) . The location of the fibrillar plaque compartment in the illustration was determined by thresholding the average PIB image for PIB + mutation carriers. The growth of the soluble, exchange, and irreversible loss compartments followed the normalized production rates for each peptide. Note that the sizes of the Ab compartments are greatly exaggerated for visualization purposes.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/5/189/189ra77/DC1 Fig. S1 . Time course of plasma leucine isotopic enrichment. 
